Performance Characteristics of Six Immunoglobulin M Enzyme-Linked Immunosorbent Assays Used for Laboratory Confirmation of Measles.


Journal

Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564

Informations de publication

Date de publication:
21 12 2022
Historique:
pubmed: 22 11 2022
medline: 24 12 2022
entrez: 21 11 2022
Statut: ppublish

Résumé

Laboratory confirmation of infection is an essential component of measles surveillance. Detection of measles-specific IgM in serum by enzyme-linked immunosorbent assay (ELISA) is the most common method used to confirm measles infection. ELISA formats vary, as does the sensitivity and specificity of each assay. Specimens collected within 3 days of rash onset can yield a false-negative result, which can delay confirmation of measles cases. Interfering substances can yield a false-positive result, leading to unnecessary public health interventions. The IgM capture assay developed at the Centers for Disease Control (CDC) was compared against five commercially available ELISA kits for the ability to detect measles virus-specific IgM in a panel of 90 well-characterized specimens. Serum samples were tested in triplicate using each commercial kit as recommended by the manufacturer. Using the CDC measles IgM capture assay as the reference test; the sensitivity and specificity for each commercial kit ranged from 50 to 83% and 86.9 to 98%, respectively. Discrepant results were observed for samples tested with all five commercial kits and ranged from 13.8 to 28.8% of the specimens tested. False-positive results occurred in 2.0 to 13.1% of sera, while negative results were observed in 16.7 to 50% of sera that were positive by the CDC measles IgM capture assay. Evaluation and interpretation of measles IgM serologic results can be complex, particularly in measles elimination settings. The performance characteristics of a measles IgM assay should be carefully considered when selecting an assay to achieve high-quality measles surveillance.

Identifiants

pubmed: 36409098
doi: 10.1128/jcm.01227-22
pmc: PMC9769589
doi:

Substances chimiques

Immunoglobulin M 0
Antibodies, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0122722

Références

Am J Epidemiol. 2017 Apr 1;185(7):562-569
pubmed: 28338902
Bull World Health Organ. 1997;75(4):367-75
pubmed: 9342896
MMWR Morb Mortal Wkly Rep. 2019 May 03;68(17):402-404
pubmed: 31048672
J Clin Microbiol. 2022 Jan 19;60(1):e0159721
pubmed: 34705533
J Infect Dis. 2004 May 1;189 Suppl 1:S43-7
pubmed: 15106088
J Infect Dis. 2004 May 1;189 Suppl 1:S1-3
pubmed: 15106120
J Pediatric Infect Dis Soc. 2013 Mar;2(1):87-90
pubmed: 26619450
J Virol Methods. 2006 Mar;132(1-2):166-73
pubmed: 16274752
J Infect Dis. 2004 May 1;189 Suppl 1:S251-7
pubmed: 15106119
MMWR Morb Mortal Wkly Rep. 2019 Oct 11;68(40):893-896
pubmed: 31600181
J Clin Microbiol. 1992 Nov;30(11):2874-80
pubmed: 1452657

Auteurs

Sun B Sowers (SB)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.

Kiana Anthony (K)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.

Sara Mercader (S)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.

Heather Colley (H)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.

Stephen N Crooke (SN)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.

Paul A Rota (PA)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.

Donald R Latner (DR)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.

Carole J Hickman (CJ)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH